Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
前收盤價
US$72.67
−US$0.03 · -0.04%
盤中時間採用ET。市場資料可能有所延遲。
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
日內區間
目前US$72.67
52週區間
目前US$72.67
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
持有
估值
48
合理估值
情緒
58
多空交錯
風險
41
風險偏高
動能
62
動能增強
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
日內區間
目前US$72.67
52週區間
目前US$72.67
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2026會計年度 | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|---|
| 營收 | 12.15億 USD | 12.2億 USD | 11.59億 USD | 11.37億 USD | 11.06億 USD |
| 銷貨成本 | 4.16億 USD | 4.29億 USD | 3.89億 USD | 3.67億 USD | 3.49億 USD |
| 毛利 | 7.99億 USD | 7.9億 USD | 7.7億 USD | 7.7億 USD | 7.56億 USD |
| 研究與開發 | 9476.6萬 USD | 9949.6萬 USD | 9666.4萬 USD | 9249.3萬 USD | 8714萬 USD |
| 銷售、一般及管理費用 | 4.52億 USD | 4.15億 USD | 3.93億 USD | 3.52億 USD | 3.39億 USD |
| 營業費用 | 5.47億 USD | 6.88億 USD | 5.63億 USD | 4.71億 USD | 4.6億 USD |
| 利息收入 | — | 388.6萬 USD | 332.3萬 USD | 341萬 USD | 79.4萬 USD |
| 利息支出 | 540.5萬 USD | 850.9萬 USD | 1573.6萬 USD | 1121.5萬 USD | 1130.9萬 USD |
| 折舊和攤銷 | 9735.9萬 USD | 1.1億 USD | 1.12億 USD | 1.07億 USD | 1.01億 USD |
| 營業利益 | 2.52億 USD | 1.02億 USD | 2.07億 USD | 2.99億 USD | 2.97億 USD |
| 淨利 | 1.82億 USD | 7340萬 USD | 1.68億 USD | 2.85億 USD | 2.72億 USD |
公司資料更新於 2026年11月22日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動,並非 GoAI 建議。
平均目標
US$71.67
下跌空間 1.38%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2022年11月30日 | 4:1 | — | — |
股票分割 | 2000年12月4日 | 2:1 | — | — |
股票分割 | 1997年11月18日 | 2:1 | — | — |
已生效 2022年11月30日
4:1
已生效 2000年12月4日
2:1
已生效 1997年11月18日
2:1
AI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。